When the high cost of branded drugs becomes a treatment barrier, the Dacomitinib version manufactured by Laos Big Bear Pharmaceutical builds a bridge between hope and affordability with reliable bioequivalence and accessible pricing.
How much is Laos Big Bear version of Dacomitinib
The Laos Big Bear version of Dacomitinib is available in specifications of 15mg*30 tablets and 45mg*30 tablets, priced at approximately $44-84. The specific price may be affected by various factors and is subject to the actual selling price.
Common adverse reactions and drug interactions of Dacomitinib
The common adverse reactions of Dacomitinib (Vizimpro, dacomitinib) in clinical application occur at a rate of over 20%, including: diarrhea, rash, paronychia (inflammation around the nails), stomatitis (mouth pain and ulcers), decreased appetite, dry skin, weight loss, alopecia, cough, and pruritus. Most of these adverse reactions are grade 1-2, but some may worsen and lead to treatment discontinuation. Regarding severe adverse reactions, among 394 patients treated with dacomitinib, the incidence of severe adverse reactions was 27%, with the most common reasons for permanent discontinuation being diarrhea and interstitial lung disease. Regarding drug interactions, special caution is required when dacomitinib is used concomitantly with the following drugs: First, proton pump inhibitors (PPIs) should be avoided concurrently with Vizimpro. It is recommended to use locally acting antacids or H2 receptor antagonists instead. If an H2 receptor antagonist must be used, Vizimpro should be administered at least 6 hours before or 10 hours after the H2 receptor antagonist. Second, CYP2D6 substrate drugs should be avoided concurrently with Vizimpro because dacomitinib may increase the plasma concentrations of these substrates, and even minor concentration increases may lead to serious or life-threatening toxicities. Patients should provide their physician with a complete list of medications before starting treatment.
What is the therapeutic effect of Dacomitinib
The U.S. Food and Drug Administration (FDA) approved dacomitinib (VIZIMPRO, Pfizer) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R substitution mutations as detected by an FDA-approved test. This approval was primarily based on a randomized, multicenter, open-label, active-controlled trial named ARCHER 1050 (NCT01774721). The study enrolled 452 patients with unresectable metastatic NSCLC who had not previously received systemic non-EGFR TKI therapy for metastatic disease or had relapsed at least 12 months after completion of systemic therapy with no disease-free status. Patients had an ECOG performance status of 0 or 1 and carried EGFR exon 19 deletions or exon 21 L858R mutations. Patients were randomized 1:1 to receive either oral dacomitinib 45 mg once daily or oral gefitinib 250 mg once daily until disease progression or unacceptable toxicity.
